SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for SNP rs11133360

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

1 Prospective Evaluation of VEGFR-2 rs11133360/IL-8 rs4073 Genetic Interaction in Metastatic Breast Cancer Patients Treated With Paclitaxel and Bevacizumab vs. Chemotherapy Alone (BEVAPROS)

Metastatic Breast cancer (MBC) patients from ten Italian Divisions of Medical Oncology, with histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1,8 and 15, every 4 weeks, will be enrolled for the present pharmacogenetic study. MBC patients treated with first-line chemotherapy including paclitaxel without bevacizumab will be also enrolled as control group.

NCT02329639 Metastatic Breast Cancer Genetic: genetic interaction analysis
MeSH:Breast Neoplasms
HPO:Breast carcinoma Neoplasm of the breast

Prospective Evaluation of VEGFR-2 rs11133360/IL-8 rs4073 Genetic Interaction in Metastatic Breast Cancer Patients Treated With Paclitaxel and Bevacizumab vs. Chemotherapy Alone (BEVAPROS).

Statistical analysis: The first aim of this prospective analysis will be evaluate the possible role of VEGFR-2 rs11133360/IL-8 rs4073 polymorphism genetic interaction to predict the bevacizumab response in terms of PFS.

Primary Outcomes

Description: progression free survival in an unselected population of metastatic breast cancer patients treated with first-line paclitaxel and bevacizumab or with chemotherapy alone, assessed through the multifactor dimensionality reduction methodology (genetic interaction analysis)

Measure: Progression free survival

Time: 24 months

Secondary Outcomes

Description: overall survival in an unselected population of metastatic breast cancer patients treated with first-line paclitaxel and bevacizumab or with chemotherapy alone, assessed through the multifactor dimensionality reduction methodology (genetic interaction analysis)

Measure: Overall survival

Time: 24 months

HPO Nodes

HP:0003002: Breast carcinoma
Genes 97
CHEK2 MLH1 PIK3CA RAD54L CTNNB1 MLH1 KLLN RAD51 NQO2 APC RAD50 TP53 STK11 RAD51C PHB RAD51C PTEN BRCA1 KRAS CDH1 AKT1 NTHL1 IDH2 MRE11 TWIST1 TP53 XRCC3 BARD1 ATR CHEK2 CDH1 BRIP1 POLE AKT1 BRCA1 TP53 MSH2 CDKN2A BARD1 PALLD SEC23B CDKN2A SEC23B STK11 NBN RB1CC1 BRCA2 RAD51 BRCA2 AAGAB POLD1 AKT1 TP53 RNF43 NTHL1 IDH1 COL14A1 BRCA2 CHEK2 PALB2 TP53 RAD51D WRN KRAS BRIP1 PPM1D SDHB SLC6A17 HMMR SMAD4 MSH2 MSH6 PRKN AKT1 USF3 ESR1 BRCA2 PTEN SDHC PALB2 CHEK2 PIK3CA CASP8 PIK3CA PIK3CA ATM MDM2 FGFR2 APC OPCML BRCA1 BRCA1 SLC22A18 BRCA1 PTEN SDHD PALB2
Protein Mutations 73
A289T A864V C3435T D538G D769H D769N D769Y D988Y E380Q E542K E545K E709K E757A G309A G309E G598V G776C G776V H1047R I655V I767M L536H L536P L536Q L536R L755P L755S L786V L841V L858R L861Q L869R P125A P12A P13K P187S P535H P596L R108K R222C R572Y R678Q R831C R831H R849W R896C S310F S310Y S463P S653C S768I S8814A S9313A T47D T733I T790M T798I T798M T862I V244M V534E V600E V659E V697L V742I V769M V773M V774M V777L V842I Y537C Y537N Y537S
SNP 38
rs1011970 rs10407022 rs1045485 rs10941679 rs10995190 rs11045585 rs11133360 rs11249433 rs12762549 rs13281615 rs13387042 rs16942 rs1800566 rs2002555 rs2046210 rs2237060 rs2241193 rs2297480 rs236114 rs2380205 rs271924 rs2981582 rs3803662 rs3817198 rs4073 rs4646 rs4973768 rs614367 rs6504950 rs6971 rs704010 rs7333181 rs7349683 rs889312 rs909253 rs9344 rs9457827 rs999737